DDInter1158 DDInter1828
An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease. Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent. Throughout the late seventies and the eighties, important research initiatives developed stable mesalazine formulations like the eudragit-S coating of Asacol brand mesalazine and the Pentasa brand's encapsulation of mesalazine within microgranules. In the present day, contemporary research regarding novel methods to stabilize mesalazine continues and interest in the agent's capacity to decrease inflammatory activity and subsequently potentially reduce the risk of colorectal cancer in conditions like ulcerative colitis is maintained.[A174019,A174022]
Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Tolbutamide appears to be metabolized in the liver. Tolbutamide and its metabolites are excreted in urine (75-85%) and feces.
Mesalazine {u} (Compound) upregulates {v} (Gene) KIAA0753
KIAA0753 {u} (Gene) is upregulated by {v} (Compound) Tolbutamide
Mesalazine {u} (Compound) causes {v} (Side Effect) Erythema
Erythema {u} (Side Effect) is caused by {v} (Compound) Tolbutamide
Mesalazine {u} (Compound) resembles {v} (Compound) Methyldopa
Methyldopa {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolbutamide
Mesalazine {u} (Compound) resembles {v} (Compound) Dopamine
Dopamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Mesalazine {u} (Compound) resembles {v} (Compound) Olsalazine
Olsalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Mesalazine {u} (Compound) upregulates {v} (Gene) KIAA0753
KIAA0753 {u} (Gene) regulates {v} (Gene) PDHX
PDHX {u} (Gene) is upregulated by {v} (Compound) Tolbutamide
Mesalazine {u} (Compound) causes {v} (Side Effect) Erythema
Erythema {u} (Side Effect) is caused by {v} (Compound) Tolazamide
Tolazamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Mesalazine {u} (Compound) resembles {v} (Compound) Methyldopa
Methyldopa {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Tolbutamide
Mesalazine {u} (Compound) resembles {v} (Compound) Dopamine
Dopamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Tolbutamide
Mesalazine {u} (Compound) resembles {v} (Compound) Olsalazine
Olsalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Tolbutamide
Mesalazine (Compound) upregulates KIAA0753 (Gene) and KIAA0753 (Gene) is upregulated by Tolbutamide (Compound)
Mesalazine (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Tolbutamide (Compound)
Mesalazine (Compound) resembles Methyldopa (Compound) and Methyldopa may cause a minor interaction that can limit clinical effects when taken with Tolbutamide
Mesalazine (Compound) resembles Dopamine (Compound) and Dopamine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Mesalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Mesalazine (Compound) upregulates KIAA0753 (Gene) and KIAA0753 (Gene) regulates PDHX (Gene) and PDHX (Gene) is upregulated by Tolbutamide (Compound)
Mesalazine (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Tolazamide (Compound) and Tolazamide (Compound) resembles Tolbutamide (Compound)
Mesalazine (Compound) resembles Methyldopa (Compound) and Methyldopa may cause a minor interaction that can limit clinical effects when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Mesalazine (Compound) resembles Dopamine (Compound) and Dopamine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Mesalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)